CYTOO is a company specialized in target discovery and selection of therapeutic candidates for the treatment of muscle and neuromuscular disorders. The company partners its versatile patient-derived muscle drug discovery engine to pharma and biotech companies and develops its own drug candidates.
Year of creation: 2008
Line of business: CRO
Institut Curie: Behind the technology and institutional co-founder
CYTOO has developed a fully mature human in vitro muscle model (MyoScreen) derived from primary human samples (healthy and pathological myoblasts) for generating NCEs from a variety of pathological conditions (rare, chronic). Core expertise lies on in vitro muscle regeneration, contraction, hypertrophy, and metabolism.
Biotechnologies & Pharmaceuticals.